Navigation Links
N30 Pharma Announces Financing, Expansion of Board
Date:10/28/2008

BOULDER, Colo., Oct. 28 /PRNewswire/ -- N30 Pharma (N30), a biopharmaceutical company focused on the discovery, development, and commercialization of drugs that regulate nitric oxide bioavailability, announced today that it has completed a financing and expanded its Board of Directors.

N30 will use proceeds from this financing to advance its clinical program in Cystic Fibrosis and expand its discovery and preclinical research in the area of small molecule drugs that modulate nitric oxide bioavailability in cardiopulmonary diseases. The financing is the company's second since its formation in 2007. Joining the company's Board of Directors are Arnold Snider and Marc Elia. Mr. Snider will assume the role of Chairman of the Board.

Mr. Snider previously founded and managed Deerfield Management, a New York-based multi-billion dollar hedge fund focused on healthcare and life-sciences companies. Mr. Snider is also on the Board of Directors of the Christopher and Dana Reeve Foundation and is a trustee of Davidson College.

Mr. Elia co-founded N30 while at Tiger Management, a New York hedge fund, and has had previous roles in life sciences corporate strategy at Chiron Corporation and L.E.K. Consulting.

"I am pleased with our investors' ongoing commitment to the major clinical potential of N30 Pharma, particularly in difficult economic times. In addition, I welcome Arnie and Marc to their roles on the Board. Arnie is widely regarded as one of the premier healthcare investors in the world. Marc brings a multitude of talents and intellect to the N30 Board. I look forward to drawing on their expertise and long experience with biopharmaceutical companies as we continue to move N30 forward," commented Charles Scoggin, M.D., President and CEO of N30.

About N30 Pharma

N30 Pharma is a clinical-stage company developing s-nitrosothiol therapies for major unmet needs in cardiopulmonary diseases. S-nitrosothiols are endogenous molecules that store and transduce nitric oxide, and are critical modulators of airway and vascular smooth muscle tone and inflammatory responses. N30 is a privately held company headquartered in Boulder, Colorado.


'/>"/>
SOURCE N30 Pharma
Copyright©2008 PR Newswire.
All rights reserved

Related biology technology :

1. Indevus Pharmaceuticals to Present at Upcoming Investor Conferences
2. Peregrine Pharmaceuticals to Present at BIO Investor Forum 2008
3. Medarex And PharmAthene Announce New Therapeutic Data for Anthrax Anti-Toxin, Valortim(R)
4. Memory Pharmaceuticals Provides Update on NASDAQ Listing Status
5. Laureate Pharma Announces Agreement with Tolera Therapeutics, Inc.
6. BioWa Announces License of Biowas Potelligent(R) Technology to KaloBios Pharmaceuticals
7. Potentia Pharmaceuticals to Present ASaP Phase I Clinical Trial Data for POT-4 at the American Academy of Ophthalmology Annual Meeting
8. Tianyin Pharmaceutical Co., Inc. to Present at Rodman & Renshaw Annual Global Investment Conference in New York City on November 11, 2008 at 12:00 p.m. EST
9. Savient Pharmaceuticals to Hold Third Quarter 2008 Financial Results Conference Call on Thursday, November 6, 2008
10. International Drug & Explosive Detection Firm Identa Corp Releasing: Jant Pharmacal Corporation Reports Successful Market Penetration of the Accutest(R) IDenta Co-brand in the United States and Oversees
11. BioCryst Pharmaceuticals To Announce Third Quarter 2008 Financial Results On October 31, 2008
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/25/2016)... ... May 25, 2016 , ... Founder of ... board-certified in surgery and surgery of the hand by the National Board of ... to going above and beyond in his pursuit of providing the most comprehensive, ...
(Date:5/25/2016)... ... May 25, 2016 , ... WEDI, the nation’s leading authority ... announced that Charles W. Stellar has been named by the WEDI Board of Directors ... 2016. As an executive leader with more than 35 years of experience in healthcare, ...
(Date:5/24/2016)... Mass. (PRWEB) , ... May 24, 2016 , ... ... heart attacks, diabetes, and traumatic injuries, will be accelerated by research at Worcester ... cells into engines of wound healing and tissue regeneration. , The novel method, ...
(Date:5/24/2016)... ... May 24, 2016 , ... Media ... The new Media Cybernetics corporate branding reflects a results-driven revitalization for a company ... analysis. The re-branding components include a crisp, refreshed logo and a new web ...
Breaking Biology Technology:
(Date:3/22/2016)... 2016 According to ... for Consumer Industry by Type (Image, Motion, Pressure, ... & IT, Entertainment, Home Appliances, & Wearable ... 2022", published by MarketsandMarkets, the market for ... USD 26.76 Billion by 2022, at a ...
(Date:3/18/2016)... --> --> Competitive Landscape ... Vehicles, Physical infrastructure and Perimeter Surveillance & Detection Systems ... market and the continuing migration crisis in the ... has led visiongain to publish this unique report, which is ... & security companies in the border security market and ...
(Date:3/15/2016)... March 15, 2016 Yissum Research Development ... technology-transfer company of the Hebrew University, announced today the ... sensing technology of various human biological indicators. Neteera Technologies ... million from private investors. ... the detection of electromagnetic emissions from sweat ducts, enables ...
Breaking Biology News(10 mins):